Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Molcan, A.
Imaging of desmoid tumours with special emphasis on peptide receptor imaging
[ Diplomarbeit ] Medical University of Graz; 2011.pp.92
[OPEN ACCESS]
FullText
- Autor*innen der Med Uni Graz:
- Betreuer*innen:
- Aigner Reingard
- Leithner Andreas
- Altmetrics:
- Abstract:
- Background: The management of desmoid tumours, especially of recurrent or inoperable desmoids, still remains problematic. MRI is considered as imaging modality of choice, though even this technique can lack to distinguish aggressive fibromatosis from other benign or malignant soft tissue masses and particular tumour relapse from postsurgical fibrosis. In 2003, de Pas and colleagues introduced a new diagnostic imaging modality for desmoid patients: The authors examined six patients with fast growing recurrences by use of somatostatin receptor scintigraphy and found that two of them had somatostatin receptor positive tumours. Subsequently they were apparently successfully treated with somatostatin receptor radionuclide therapy, in terms of partial response in one case and disease stabilisation in the other case. Objective: The aim of this study was to investigate the percentage of desmoid tumours, which express somatostatin receptor 2 and show adequate tracer uptake in somatostatin receptor scintigraphy and moreover to correlate these results with immunohistochemical staining of the somatostatin receptor subtype 2A. Patients and methods: 13 patients with desmoid tumours were included and have been examined with somatostatin receptor scintigraphy. Additionally, seven of these patients have been tested for the immunohistochemical expression of somatostatin receptor subtype 2A. Mean age at diagnosis was 38 years (range, 18 to 52 years). The results of somatostatin receptor scintigraphy and the correlation with an immunohistochemical staining of somatostatin receptor subtype 2A were evaluated. Results: Somatostatin receptor scintigraphy revealed that eight out of 13 patients (62%) showed enhanced tracer uptake at the site of the desmoid. Therefore these desmoids are somatostatin receptor positive tumours. The overall correlation of somatostatin receptor scintigraphy and immunohistochemical investigations for somatostatin receptor subtype 2A was poor and appeared to correlate in only two out of seven cases. Conclusion: By means of somatostatin receptor scintigraphy, the current study has demonstrated that desmoid tumours frequently express somatostatin receptor subtype 2. Except for two cases, immunohistochemical investigations for somatostatin receptor subtype 2A did not correlate with somatostatin receptor scintigraphy findings. This may likely be due to lack of standardisation of this technique and also due to heterogeneous receptor distribution within the tumours. Further investigations are needed to determine the value of both techniques for desmoid tumours.